Open AccessTreatment of cytokine storm syndrome with IL‐1 receptor antagonist anakinra in a patient with ARDS caused by COVID‐19 infection: A case report
Author(s) -
Kaps Leonard,
Labenz Christian,
Grimm Daniel,
Schwarting Andreas,
Galle Peter R.,
Schreiner Oliver
Publication year - 2020
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.3307
Subject(s) - anakinra , cytokine storm , medicine , ards , cytokine release syndrome , immunosuppression , covid-19 , cytokine , sepsis , receptor antagonist , immunology , antagonist , intensive care medicine , receptor , virology , lung , infectious disease (medical specialty) , disease , outbreak
The biological anakinra appears promising to halt cytokine storm syndrome seen in severe courses of COVID‐19. However, immunosuppression with anakinra may facilitate sepsis, necessitating continuous screening for bacterial superinfections.